TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Device
Description: Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fillet Technique
Description: Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fillet Technique
Description: Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
Study: NCT02652949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Evo Thoracic Stent Graft System
Description: Procedure: thoracic endovascular aneurysm repair (TEVAR)
Study: NCT00488189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazocin (pipercillin/tazobactam)
Description: over 50% third generation cephalosporin should be replaced by Pip/Taz
Study: NCT04349202

Intervention type: DIAGNOSTIC_TEST
Intervention: EUROIMMUN assay
Description: Serology testing to detect SARS-CoV-2 antibodies
Study: NCT01061593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoxel
Description: 1 lozenge once per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 lozenge once per day
Study: NCT01542814

Intervention type: DEVICE
Intervention: 3Dimensional Mammography
Description: The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.

Intervention type: DEVICE
Intervention: 2D FFDM
Description: Standard of care screening mammogram.
Study: NCT03442218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorhexidine
Description: Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
Study: NCT05127239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application with lifestyle modification Intervention
Description: The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application with lifestyle modification Intervention
Description: The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
Study: NCT04036942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the gastroesophageal junction with hybrid argon plasma
Description: In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucosectomy with band of the gastroesophageal junction
Description: In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
Study: NCT04296981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based patient information
Description: explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
Study: NCT01726738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Description: Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
Study: NCT02313753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLASP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAFE
Study: NCT02676531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking meditation exercise program
Study: NCT03026465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-free stent
Description: PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodegradable-polymer stent
Description: PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
Study: NCT01280695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 100 mg
Description: MSDC-0602 100 mg Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 250 mg
Description: MSDC-0602 250 mg Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 250 mg
Description: MSDC-0602 500 mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg Capsules
Study: NCT02900768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Combination of resistance and aerobic exercises for 100 days.
Study: NCT04087577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: mirror therapy
Study: NCT02218593

Intervention type: DEVICE
Intervention: WREX orthosis
Description: Upper extremity exoskleton used to assist movement
Study: NCT02902393

Intervention type: BIOLOGICAL
Intervention: Thromboelastography
Study: NCT02602158

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Octanoic acid (1-13C, 99%)
Description: 13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRIOCTANOIN (1,1,1-13C3, 99%)
Description: 13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
Study: NCT02315560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS
Description: electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
Study: NCT01456312

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Duration and combination

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Duration and combination

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Duration and combination

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Entecavir
Description: combination
Study: NCT02650063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Study: NCT04079998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera®
Description: Application of Procellera® dressing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Application of standard of care dressings as prescribed.
Study: NCT03009617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the educational program and counseling
Description: to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
Study: NCT02736916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HS-WBRT PCI
Description: LD-SCLC patients with HS-WBRT PCI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: LD-SCLC patients with conventional PCI
Study: NCT00520910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos
Description: Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
Study: NCT03620084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Description: The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
Study: NCT02736435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Guided High Intensity Focused Ultrasound
Description: Direct treatment of uterine fibroids with MR-HIFU
Study: NCT01403324

Intervention type: DRUG
Group type: OTHER
Intervention: TSH stimulation
Description: rh TSH stimulation followed by thyroid hormon withdrawal
Study: NCT01884675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White, film-coated, ambrisentan-matching placebo tablet for single oral dose
Study: NCT00218439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 10 mg for 1 week followed by 20 mg for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 10 mg for 1 week followed by 20 mg for 3 weeks
Study: NCT02009722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
Study: NCT01494259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
Study: NCT02794727

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blinded Fitbit
Description: Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
Study: NCT01076504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
Study: NCT00218439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03297463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 & Ipilimumab (P-Ib)
Description: Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 & Ipilimumab (P-II)
Description: Phase II:~- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D).
Study: NCT01076504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 IV, Day 1 of each 3-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SQ on Day 4 of each 3 week treatment cycle
Study: NCT00915512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Description: Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
Study: NCT03691831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: A-101 45% (hydrogen peroxide 45% topical solution)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle solution containing isopropyl alcohol and water
Study: NCT00542321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual turn
Description: Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinetic therapy bed
Description: Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
Study: NCT03260543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented ginseng powder
Description: tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study: NCT03954054

Intervention type: BEHAVIORAL
Intervention: Choizitaconso - therapeutic patient education programme
Description: Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons.

Intervention type: BEHAVIORAL
Intervention: Choizitaconso - therapeutic patient education programme
Description: Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons.
Study: NCT02502591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pudendal Nerve Block
Description: An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
Study: NCT02497274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taste assessment and epithelium gustatory smear and biopsy
Description: assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taste assessment and epithelium gustatory smear and biopsy
Description: assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
Study: NCT02101866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 300 mg tablet
Description: tablet - single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 132 mg capsules
Description: 2 capsules - single dose
Study: NCT03581708

Intervention type: OTHER
Intervention: lung cancer
Description: If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
Study: NCT02794727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unblinded Fitbit
Description: Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
Study: NCT00547586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02736435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Guided High Intensity Focused Ultrasound
Description: Direct treatment of uterine fibroids with MR-HIFU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate for depot suspension
Description: Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
Study: NCT01248741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR prostate brachytherapy
Description: HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy
Study: NCT03043391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio/Rhinovirus Recombinant (PVSRIPO)
Description: PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.